Hansoh Pharmaceutical's B7-H3-Targeted Antibody-Drug Conjugate HS-20093 Receives EMA PRIME Designation

Hansoh Pharma (03692) announced that GSK’s GSK5764227 (GSK’227, also known as HS-20093), a B7-H3-targeted antibody-drug conjugate (ADC), has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA). This ADC is currently being evaluated for the treatment of patients with relapsed extensive-stage small cell lung cancer (ES-SCLC).